{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T14:51:06Z","timestamp":1773499866130,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T00:00:00Z","timestamp":1544140800000},"content-version":"am","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["CA130460"],"award-info":[{"award-number":["CA130460"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2016R1A2B4006914"],"award-info":[{"award-number":["NRF-2016R1A2B4006914"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Donald B. & Dorothy L. Stabler Foundation"},{"name":"Jerome L. Greene Fund"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jconrel.2017.10.004","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T14:55:10Z","timestamp":1507820110000},"page":"163-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["PEGylated TRAIL ameliorates experimental inflammatory arthritis by regulation of Th17 cells and regulatory T cells"],"prefix":"10.1016","volume":"267","author":[{"given":"Jong-Sung","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumin","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ogyi","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine A.","family":"Foss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Mook","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Gyu","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Hee","family":"Na","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang Choon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seulki","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2017.10.004_bb0005","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","article-title":"New therapies for treatment of rheumatoid arthritis","volume":"370","author":"Smolen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2017.10.004_bb0010","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMct055183","article-title":"Tumor necrosis factor inhibitors for rheumatoid arthritis","volume":"355","author":"Scott","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2017.10.004_bb0015","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2666","article-title":"Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review","volume":"11","author":"Rubbert-Roth","year":"2009","journal-title":"Arthritis Res. & Ther."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0020","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature01661","article-title":"Evolving concepts of rheumatoid arthritis","volume":"423","author":"Firestein","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2017.10.004_bb0025","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0030","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","article-title":"Role of cytokines in rheumatoid arthritis","volume":"14","author":"Feldmann","year":"1996","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0035","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri2094","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis","volume":"7","author":"McInnes","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0040","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/ncprheum0142","article-title":"T-cell-targeted therapies in rheumatoid arthritis","volume":"2","author":"Weyand","year":"2006","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/5517","article-title":"Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo","volume":"5","author":"Walczak","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0050","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/nrc2465","article-title":"The TRAIL apoptotic pathway in cancer onset, progression and therapy","volume":"8","author":"Johnstone","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2017.10.004_bb0055","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/cdd.2014.81","article-title":"Getting TRAIL back on track for cancer therapy","volume":"21","author":"Lemke","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0060","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2007.15.7198","article-title":"Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2\/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L\/TRAIL)","volume":"26","author":"Ashkenazi","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0065","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/cdd.2015.174","article-title":"Onto better TRAILs for cancer treatment","volume":"23","author":"de Miguel","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0070","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1158\/1535-7163.MCT-09-1076","article-title":"Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand","volume":"9","author":"Chae","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0075","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1021\/bc200187k","article-title":"PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects","volume":"22","author":"Kim","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0080","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jconrel.2015.09.014","article-title":"Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors","volume":"220","author":"Oh","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.10.004_bb0085","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.28432","article-title":"Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells","volume":"64","author":"Oh","year":"2016","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.jconrel.2017.10.004_bb0090","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0008-8749(02)00602-0","article-title":"Suppression of antibody production by TNF-related apoptosis-inducing ligand (TRAIL)","volume":"219","author":"Kayagaki","year":"2002","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0095","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1084\/jem.191.7.1095","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression","volume":"191","author":"Song","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0100","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ni894","article-title":"Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL\u2212\/\u2212 mice","volume":"4","author":"Lamhamedi-Cherradi","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0105","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1440-1711.2005.01358.x","article-title":"TNF-related apoptosis-inducing ligand (TRAIL)\/Apo2L suppresses experimental autoimmune encephalomyelitis in mice","volume":"83","author":"Cretney","year":"2005","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0110","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.2337\/diabetes.52.9.2274","article-title":"Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes","volume":"52","author":"Lamhamedi-Cherradi","year":"2003","journal-title":"Diabetes"},{"issue":"2010","key":"10.1016\/j.jconrel.2017.10.004_bb0115","first-page":"5259","article-title":"Dual effects of TRAIL in suppression of autoimmunity: the inhibition of Th1 cells and the promotion of regulatory T cells","volume":"185","author":"Ikeda","year":"1950","journal-title":"J. Immunol (Baltimore, MD)"},{"key":"10.1016\/j.jconrel.2017.10.004_bb0120","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/sj.cdd.4402220","article-title":"Involvement of cellular death in TRAIL\/DR5-dependent suppression induced by CD4(+)CD25(+) regulatory T cells","volume":"14","author":"Ren","year":"2007","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0125","doi-asserted-by":"crossref","first-page":"9057","DOI":"10.1016\/j.biomaterials.2010.08.015","article-title":"Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosis-inducing ligand for treatment of rheumatoid arthritis","volume":"31","author":"Kim","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2017.10.004_bb0130","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1124\/jpet.109.159517","article-title":"Effect of tumor necrosis factor-related apoptosis-inducing ligand on the reduction of joint inflammation in experimental rheumatoid arthritis","volume":"332","author":"Jin","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0135","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/annrheumdis-2013-203467","article-title":"Inhibition of notch signalling ameliorates experimental inflammatory arthritis","volume":"74","author":"Park","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0140","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbrc.2015.03.171","article-title":"Molecular imaging of inflammation in the ApoE -\/- mouse model of atherosclerosis with IodoDPA","volume":"461","author":"Foss","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0145","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1093\/infdis\/jit331","article-title":"Noninvasive molecular imaging of tuberculosis-associated inflammation with radioiodinated DPA-713","volume":"208","author":"Foss","year":"2013","journal-title":"J Infect Dis"},{"issue":"2003","key":"10.1016\/j.jconrel.2017.10.004_bb0150","first-page":"1061","article-title":"TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis","volume":"171","author":"Ichikawa","year":"1950","journal-title":"J. Immunol. (Baltimore, MD)"},{"key":"10.1016\/j.jconrel.2017.10.004_bb0155","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1002\/art.20501","article-title":"Rheumatoid arthritis synovial fluid fibroblasts express TRAIL-R2 (DR5) that is functionally active","volume":"50","author":"Miranda-Carus","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0160","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI11830","article-title":"NF-kappaB: a key role in inflammatory diseases","volume":"107","author":"Tak","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0165","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1517\/14728222.11.2.111","article-title":"As a therapeutic target in autoimmune disease","volume":"11","author":"O'Sullivan","year":"2007","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jconrel.2017.10.004_bb0170","first-page":"651503","article-title":"Th17 cells in autoimmune and infectious diseases","volume":"2014","author":"Zambrano-Zaragoza","year":"2014","journal-title":"Int. J. Inflamm."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0175","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0180","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.4049\/jimmunol.1301454","article-title":"IL-21-producing Th cells in immunity and autoimmunity","volume":"191","author":"Liu","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0185","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ncprheum0624","article-title":"CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases","volume":"3","author":"Valencia","year":"2007","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0190","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nri2889","article-title":"Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases","volume":"10","author":"Buckner","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0195","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1084\/jem.20061531","article-title":"Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta","volume":"204","author":"Nadkarni","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0200","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/nprot.2006.393","article-title":"Collagen antibody-induced arthritis","volume":"1","author":"Khachigian","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0205","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/ar86","article-title":"Macrophages in rheumatoid arthritis","volume":"2","author":"Kinne","year":"2000","journal-title":"Arthritis Res."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0210","doi-asserted-by":"crossref","first-page":"R70","DOI":"10.1186\/ar4509","article-title":"Promising potential of new generation translocator protein tracers providing enhanced contrast of arthritis imaging by positron emission tomography in a rat model of arthritis","volume":"16","author":"Gent","year":"2014","journal-title":"Arthritis Res. & Ther."},{"key":"10.1016\/j.jconrel.2017.10.004_bb0215","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaneurol.2016.3764","article-title":"Imaging of glial cell activation and white matter integrity in brains of active and recently retired National Football League Players","volume":"74","author":"Coughlin","year":"2017","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.jconrel.2017.10.004_bb0220","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.117.189571","article-title":"Imaging macrophage accumulation in a murine model of chronic pancreatitis with [125I]iodoDPA SPECT-CT","author":"Foss","year":"2017","journal-title":"J. Nucl. Med."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591730891X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591730891X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:33:20Z","timestamp":1759160000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836591730891X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":44,"alternative-id":["S016836591730891X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.10.004","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PEGylated TRAIL ameliorates experimental inflammatory arthritis by regulation of Th17 cells and regulatory T cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}